LEADERSHIP.
EMPOWERMENT.
DEVELOPMENT.
Chicago Lymphoma Symposium 2022 Program Overview
Target Audience
This activity has been designed for practicing oncologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma
- Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma
- Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data
- Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL
- Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma
| Time (EST) | Presentation | Faculty |
| Friday, April 29 | Interprofessional Session | Presenter |
| 8:00 – 8:15 AM | Welcome and Introductions | |
| 8:15 – 9:15 AM | Palliative Care | |
| 9:15 – 10:15 AM | Psychosocial support – anxiety, depression in lymphoma patients | |
| 10:15 – 10:30 AM | Survivorship | |
| 10:30 – 11:00 AM | Break/Virtual Exhibits | |
| 11:00 – 11:45 AM | Supportive Therapies for Novel Oral Therapies | |
| 11:45 – 12:30 PM | Multidisciplinary Approach to care management | |
| 12:30 – 12:45 PM | Q&A | |
| 12:45 – 12:55 PM | Session Wrap-Up and Closing |
Friday, April 29, 2022
General Session Day 1
| Time (EST) | General Session | Presenter |
| 1:00 – 1:10 PM | Welcome and Introductions | Moderator |
| 1:10 – 3:00 PM | Mini Symposium on Follicular Lymphoma (FL) | Moderator |
|
1:10 – 1:15 PM Pre-session ARS 1:15 – 1:35 PM: Biology of FL
1:35 – 1:55 PM: Targeted agents in FL – How to choose?
1:55 – 2:15 PM: Immunotherapy for FL (Caron Jacobson?)
2:15 – 2:35 PM: Management of the FL patient in the COVID era
2:35 – 3:00 PM: Panel discussion with speakers, Q&A, and post-session ARS |
Robert Kridel
Tycel Phillips (Michigan)
Sairah Ahmed (MDACC)
Leo Gordon (NU) |
|
| 13:00 – 3:30 PM | Break & Exhibits | |
| 3:30 – 4:55 PM | Mini Symposium on Mantle Cell Lymphoma (MCL) | Moderator |
|
3:30 – 3:50 PM: Case presentations – how would you treat? (with ARS)
|
Reem Karmali
Kami Maddocks |
|
| 4:55 – 5:00 PM | General Session Wrap Up and Summary | IUCLS Chairs |
Saturday, April 30, 2022
General Session Day 2
|
Time (EST) |
General Session |
Presenter |
|
8:00 – 8:10 AM |
Welcome and Introductions |
Moderator |
|
8:10 – 10:00 AM |
Mini Symposium on Hodgkin Lymphoma (HL) |
|
|
8:10 – 8:15 AM: Pre-session ARS 8:15 – 8:35 AM: Impact of the immune landscape on Hodgkin lymphoma prognosis and treatment (Margaret Shipp or someone in her lab?) 8:35 – 8:55 AM: Treatment of 1st relapsed HL (Vaishalee Kenkre) 8:55 – 9:15 AM: Relapse after auto SCT, brentuximab vedotin, and checkpoint inhibitors – the next frontier
9:15 – 9:35 AM: Post-acute (years 1-10) outcomes in HL (Lindsay Morton) 9:35 – 10:00 AM: Speaker panel discussion, audience Q&A, and post-session ARS |
Christian Steidl (BCA)
Vaishalee Kenkre (Wisconsin)
Lindsay Morton |
|
|
10:00 – 10:15 AM |
Break & Virtual Exhibits |
|
|
10:15 – 11:35 AM |
Primary and Secondary CNS Lymphoma |
Moderator |
|
10:15 – 10:20 AM: Pre-session ARS 10:20 – 10:40 AM Primary CNS lymphoma – focus on consolidation (Tracy Batchelor?)
10:40 – 11:10 AM CNS lymphoma prophylaxis 11:10 – 11:30 AM: Treatment of relapsed primary and secondary CNS lymphoma (Mark Roschewski?)
11:30 – 11:35 AM: Audience Q&A |
Tracy Batchelor
Craig Portell
Andres Ferreri |
|
|
11:35 AM – 12:35 PM |
Keynote Symposium: CLL |
|
|
11:35 AM – 12:35 PM: Limited duration treatment of relapsed CLL: are we there yet?
|
||
|
12:35 – 1:00 PM |
Lunch & Exhibits |
|
|
1:00 – 2:50 PM |
Mini Symposium on Aggressive Lymphoma |
Moderator |
|
1:00 – 2:50 PM |
1:00 – 1:05 PM: Pre-session ARS 1:05 – 1:25 PM: HBGL NOS: how to differentiate and what to do? (David Scott) 1:25 – 1:45 PM: Prognostication and treatment of Burkitt lymphoma in the modern era (Adam Olszewski) 1:45 – 2:05 PM: When is R-CHOP not the preferred regimen for newly diagnosed DLBCL?
2:05 – 2:25 PM: How to sequence non-CAR T-cell therapy for relapsed DLBCL 2:25 – 2:50 PM: Speaker panel discussion, audience Q&A, and post-session ARS |
David Scott
Adam Olszewski
Laurie Sehn
Dan Landsburg |
|
2:50 – 4:15 PM |
Mini Symposium on Next Generation Cellular and Targeted Therapies |
|
|
2:50 – 2:55 PM Pre-session ARS 2:55 – 3:15 PM Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies 3:15 –3:35 PM New CART Constructs: What is on the Horizon? (Tonya Siddiqui) 3:35 – 3:55 PM Bispecific Antibodies (Martin Hutching) 3:55 – 4:20 PM: Speaker panel discussion, audience Q&A, and post-session ARS |
Jeremy Abramson
Tonya Siddiqui
Martin Hutching |
|
|
4:20 – 4:35 PM |
Summary and Best of IUCLS |
IUCLS Chairs |
|
4:35 PM |
Adjourn |
